

October 6, 2022

Ying Huang, Ph.D  
Chief Financial Officer  
Legend Biotech Corporation  
2101 Cottontail Lane  
Somerset, NJ 08873

Re: Legend Biotech Corp  
Form 20-F for

Fiscal Year Ended December 31, 2021  
September 30, 2022

Response Dated

File No. 001-39307

Dear Ying Huang:

We have reviewed your September 30, 2022 response to our comment letter and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our September 2, 2022 letter.

Form 20-F for Fiscal Year Ended December 31, 2021

Certain Information, page 1

1. We note your response to comment 1 and re-issue in part. Please clarify that the legal and operational risks associated with operating in China also apply to operations in Hong Kong and Macau.

Ying Huang, Ph.D  
FirstName LastNameYing Huang, Ph.D  
Legend Biotech Corporation  
Comapany  
October NameLegend Biotech Corporation  
6, 2022

October  
Page 2 6, 2022 Page 2

FirstName LastName  
D. Risk Factors  
Risk Factor Summary, page 4

2. Please revise your summary of risk factors so that you disclose the risks that the Chinese government may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in your operations and/or the value of your securities. Moreover, in the summary of risk factors, please acknowledge any risks that any actions by the Chinese government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers could significantly limit or completely hinder your ability to offer or continue to offer securities to investors and cause the value of your securities to significantly decline or be worthless. The audit report included in this Annual Report is prepared by an auditor who

is not inspected by  
the Public Company Accounting. . . , page 69

3. We note your response to comment 10, including your disclosure discussing the August 26, 2022 Statement of Protocol. Please revise your disclosure to clarify that the PCAOB will be required to reassess its determinations by the end of 2022. You may contact Li Xiao at 202-551-4391 or Daniel Gordon at 202-551-3486 if you have questions regarding comments on the financial statements and related matters. Please contact Dillon Hagijs at 202-551-7967 or Jason Drory at 202-551-8342 with any other questions.

Sincerely,

Division of

Office of Life

Corporation Finance

Sciences

cc: Mark Ballantyne